<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351608</url>
  </required_header>
  <id_info>
    <org_study_id>8616-089</org_study_id>
    <secondary_id>2017-000692-92</secondary_id>
    <secondary_id>MK-8616-089</secondary_id>
    <nct_id>NCT03351608</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)</brief_title>
  <official_title>A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the efficacy, safety, and pharmacokinetics of sugammadex for the
      reversal of both moderate and deep neuromuscular blockade (NMB) induced by either rocuronium
      or vecuronium in pediatric participants. The primary efficacy hypothesis of this
      investigation is that sugammadex is superior to neostigmine in reversing moderate NMB in
      pediatric participants as measured by time to recovery to a train-of-four (TOF) ratio of
      ≥0.9.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will be conducted in two parts: Part A and Part B. In Part A, pharmacokinetic (PK)
      sampling will be conducted to identify the pediatric dose providing sugammadex exposure
      similar to adults. For Part B participants, the efficacy of sugammadex (i.e. time to recovery
      of the TOF ratio) will be assessed. Further, safety analyses will be conducted in both Parts
      A and B. Following completion of Part A, an interim analysis (IA) of the PK and safety data
      will be performed. Once the appropriate doses are confirmed and safety data is assessed for
      the 2 doses of sugammadex, then Part B will commence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Actual">January 28, 2020</completion_date>
  <primary_completion_date type="Actual">January 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC) for Sugammadex [Part A]</measure>
    <time_frame>2 minutes (min), 15 min, 30 min, 60 min, 5 hours (hrs), and 10 hrs post-dose</time_frame>
    <description>Blood samples will be collected at prespecified time points to determine AUC, defined as the area under the curve of the plasma sugammadex concentration vs. time plot.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Clearance (CL) of Sugammadex [Part A]</measure>
    <time_frame>2 min, 15 min, 30 min, 60 min, 5 hrs, and 10 hrs post-dose</time_frame>
    <description>Blood samples will be collected at prespecified time points to determine CL, defined as the rate of elimination relative to plasma concentration of sugammadex.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz) of Sugammadex [Part A]</measure>
    <time_frame>2 min, 15 min, 30 min, 60 min, 5 hrs, and 10 hrs post-dose</time_frame>
    <description>Blood samples will be collected at prespecified time points to determine Vz, defined as the amount of sugammadex administered relative to plasma sugammadex concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Sugammadex [Part A]</measure>
    <time_frame>2 min, 15 min, 30 min, 60 min, 5 hrs, and 10 hrs post-dose</time_frame>
    <description>Blood samples will be collected at prespecified time points to determine Cmax, defined as the maximum plasma concentration of sugammadex post-administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Half-Life of Sugammadex [Part A]</measure>
    <time_frame>2 min, 15 min, 30 min, 60 min, 5 hrs, and 10 hrs post-dose</time_frame>
    <description>Blood samples will be collected at prespecified time points to determine plasma half-life, defined as the time required for the plasma sugammadex concentration to decrease to 50% of maximum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs) [Parts A and B]</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Following administration of study intervention, the number of participants experiencing an AE will be assessed. An AE is defined as any unfavorable and unintended medical occurrence, symptom, or disease witnessed in a participant, regardless of whether or not a causal relationship with the study treatment can be demonstrated. Further, any worsening of a preexisting condition that is temporally associated with the use of the study treatment is also considered an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Recovery of Participant Train-Of-Four (TOF) Ratio to ≥0.9 [Part B]</measure>
    <time_frame>Up to 30 minutes post-dose</time_frame>
    <description>Following administration of study intervention, the time to recovery of participant TOF ratio to ≥0.9 will be assessed. The TOF ratio is the ratio of the magnitude of the fourth (T4) and first (T1) thumb twitches elicited by 4 electrical stimulations of the ulnar nerve, indicating the current degree of NMB as a decimal from 0 (loss of T4 twitch) to 1 (no NMB), with greater values indicating less NMB.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery of Participant Train-Of-Four (TOF) Ratio to ≥0.8 [Part B]</measure>
    <time_frame>Up to 30 minutes post-dose</time_frame>
    <description>Following administration of study intervention, the time to recovery of participant TOF ratio to ≥0.8 will be assessed. The TOF ratio is the ratio of the magnitude of the fourth (T4) and first (T1) thumb twitches elicited by 4 electrical stimulations of the ulnar nerve, indicating the current degree of NMB as a decimal from 0 (loss of T4 twitch) to 1 (no NMB), with greater values indicating less NMB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery of Participant Train-Of-Four (TOF) Ratio to ≥0.7 [Part B]</measure>
    <time_frame>Up to 30 minutes post-dose</time_frame>
    <description>Following administration of study intervention, the time to recovery of participant TOF ratio to ≥0.7 will be assessed. The TOF ratio is the ratio of the magnitude of the fourth (T4) and first (T1) thumb twitches elicited by 4 electrical stimulations of the ulnar nerve, indicating the current degree of NMB as a decimal from 0 (loss of T4 twitch) to 1 (no NMB), with greater values indicating less NMB.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Sugammadex 2 mg/kg (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (i.v.) bolus of sugammadex at 2 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 4 mg/kg (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single i.v. bolus of sugammadex at 4 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 2 mg/kg (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single i.v. bolus of sugammadex at 2 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 4 mg/kg (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single i.v. bolus of sugammadex at 4 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine (Part B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single i.v. bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 2 mg/kg</intervention_name>
    <description>For moderate NMB reversal, a single i.v. bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.</description>
    <arm_group_label>Sugammadex 2 mg/kg (Part A)</arm_group_label>
    <arm_group_label>Sugammadex 2 mg/kg (Part B)</arm_group_label>
    <other_name>MK-8616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 4 mg/kg</intervention_name>
    <description>For deep NMB reversal, a single i.v. bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).</description>
    <arm_group_label>Sugammadex 4 mg/kg (Part A)</arm_group_label>
    <arm_group_label>Sugammadex 4 mg/kg (Part B)</arm_group_label>
    <other_name>MK-8616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine + Glycopyrrolate</intervention_name>
    <description>For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.</description>
    <arm_group_label>Neostigmine (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine + Atropine</intervention_name>
    <description>For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.</description>
    <arm_group_label>Neostigmine (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be categorized as American Society of Anesthesiologists (ASA) Physical Status Class 1,
             2, or 3.

          -  Have a planned non-emergent surgical procedure or clinical situation (e.g.,
             intubation) that requires moderate or deep NMB with either rocuronium or vecuronium.

          -  Have a planned surgical procedure or clinical situation that would allow objective
             neuromuscular monitoring techniques to be applied with access to the arm for
             neuromuscular transmission monitoring.

          -  Age between 2 to &lt;17 years at Visit 2.

          -  If female, may participate if she is not pregnant, not breastfeeding, and at least one
             of the following: 1) Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who
             agrees to follow the study contraceptive guidance during the treatment period and for
             at least 7 days after the last dose of study treatment.

        Exclusion Criteria:

          -  Has any clinically significant condition or situation (eg, anatomical malformation
             that complicates intubation) other than the condition being studied that, in the
             opinion of the investigator, would interfere with the trial evaluations or optimal
             participation in the trial.

          -  Has a neuromuscular disorder that may affect NMB and/or trial assessments.

          -  Is dialysis-dependent or has (or is suspected of having) severe renal insufficiency
             (defined as estimated glomerular filtration rate (eGFR) &lt;30 ml/min).

          -  Has or is suspected of having a family or personal history of malignant hyperthermia.

          -  Has or is suspected of having an allergy to study treatments or its/their excipients,
             to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used
             during general anesthesia.

          -  Has received or is planned to receive toremifene and/or fusidic acid via IV
             administration within 24 hours before or within 24 hours after administration of study
             treatment.

          -  Has been previously treated with sugammadex or has participated in a sugammadex
             clinical trial.

          -  Is currently participating in or has participated in an interventional clinical trial
             with an investigational compound or device within 30 days of signing the informed
             consent/assent for this current trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles ( Site 0030)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille Packard Children's Hospital ( Site 0006)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego ( Site 0035)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center ( Site 0008)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital/ University of Michigan Medical center ( Site 0014)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-4245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital [New Brunswick, NJ] ( Site 0009)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center ( Site 0019)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia ( Site 0015)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC ( Site 0005)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Medical Center University of Texas Medical School ( Site 0038)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University ( Site 0043)</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sozialmedizinisches Zentrum Ost - Donauspital ( Site 0150)</name>
      <address>
        <city>Wien</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Antwerpen - UZA ( Site 0200)</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Campus Gasthuisberg ( Site 0201)</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet ( Site 0250)</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Childrens Hospital ( Site 0750)</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakovere Annastift gGmbH ( Site 0354)</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen und Marburg GmbH ( Site 0355)</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar Technische Universitaet Muenchen ( Site 0350)</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Franziskus-Hospital ( Site 0352)</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Steinenberg Reutlingen ( Site 0351)</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephs-Hospitals Warendorf ( Site 0353)</name>
      <address>
        <city>Warendorf</city>
        <zip>48231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Lucia ( Site 0501)</name>
      <address>
        <city>Cartagena</city>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nino Jesus ( Site 0503)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0502)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra ( Site 0500)</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tip Fakultesi ( Site 0551)</name>
      <address>
        <city>Ankara</city>
        <zip>06620</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag Universitesi Tip Fakultesi ( Site 0553)</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koc Universitesi Hastanesi ( Site 0555)</name>
      <address>
        <city>Istanbul</city>
        <zip>34010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0552)</name>
      <address>
        <city>Istanbul</city>
        <zip>34040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

